ZOTA
Zota Health Care LImited
Pharmaceutical and healthcare company with retail pharmacy and IT services
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Zota Health Care runs Davaindia, a chain of 2,825 stores (June 2026) selling quality generic medicines at affordable prices across India, and also makes and sells pharmaceutical products in India and for export.
Company snapshot
60thBy market cap
Ranked among 119 companies in Pharmaceuticals.
What we see
- ✓Debt-to-equity of 0.04x — the company is largely funded by its own money, not borrowed funds.
- ✗Net margin is negative — the company is spending more than it earns right now.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 45 Cr | 47 Cr | 50 Cr | 56 Cr | 67 Cr | 72 Cr | 97 Cr | 104 Cr | 129 Cr | 143 Cr | 163 Cr | 174 Cr |
| Operating expenses (approx.) | 41 Cr | 44 Cr | 51 Cr | 58 Cr | 68 Cr | 78 Cr | 95 Cr | 100 Cr | 123 Cr | 143 Cr | 154 Cr | 185 Cr |
| EBITDA | 4 Cr | 3 Cr | -1 Cr | -1 Cr | -0.87 Cr | -6 Cr | 2 Cr | 4 Cr | 6 Cr | -0.44 Cr | 9 Cr | -12 Cr |
| OPM % | 9.8% | 7.1% | -3.0% | -2.2% | -1.3% | -8.4% | 2.5% | 3.8% | 4.9% | -0.3% | 5.3% | -6.7% |
| Other income | 0.40 Cr | 0.15 Cr | 0.46 Cr | 0.02 Cr | 0.54 Cr | 0.51 Cr | 1 Cr | 0.88 Cr | 2 Cr | 2 Cr | 3 Cr | 2 Cr |
| Interest | 1 Cr | 1 Cr | 2 Cr | 3 Cr | 3 Cr | 2 Cr | 3 Cr | 3 Cr | 4 Cr | 5 Cr | 5 Cr | 6 Cr |
| Depreciation | 5 Cr | 5 Cr | 7 Cr | 8 Cr | 10 Cr | 11 Cr | 14 Cr | 15 Cr | 19 Cr | 22 Cr | 27 Cr | 28 Cr |
| Profit before tax | -1 Cr | -3 Cr | -10 Cr | -12 Cr | -13 Cr | -18 Cr | -14 Cr | -13 Cr | -14 Cr | -26 Cr | -26 Cr | -44 Cr |
| Tax % | -48.8% | -7.5% | 27.2% | -4.6% | 4.0% | -2.5% | 9.9% | -5.3% | -12.6% | -14.2% | 45.3% | -0.7% |
| Net profit | -2 Cr | -3 Cr | -7 Cr | -13 Cr | -12 Cr | -19 Cr | -13 Cr | -14 Cr | -16 Cr | -30 Cr | -14 Cr | -44 Cr |
| EPS (₹) | ₹-0.64 | ₹-1.14 | ₹-2.68 | ₹-4.80 | ₹-4.57 | ₹-6.80 | ₹-4.57 | ₹-4.92 | ₹-5.26 | ₹-9.44 | ₹-4.13 | ₹-12.58 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 86 Cr | 95 Cr | 107 Cr | 131 Cr | 140 Cr | 180 Cr | 293 Cr | 539 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 78 Cr | 91 Cr | 106 Cr | 116 Cr | 133 Cr | 173 Cr | 299 Cr | 520 Cr | Sign in free for the trailing twelve months |
| EBITDA | 8 Cr | 5 Cr | 0.62 Cr | 15 Cr | 7 Cr | 8 Cr | -6 Cr | 19 Cr | Sign in free for the trailing twelve months |
| OPM % | 9.0% | 4.7% | 0.6% | 11.3% | 5.2% | 4.2% | -2.0% | 3.4% | Sign in free for the trailing twelve months |
| Other income | 2 Cr | 2 Cr | 1 Cr | 2 Cr | 2 Cr | 1 Cr | 2 Cr | 7 Cr | Sign in free for the trailing twelve months |
| Interest | 0.04 Cr | 0.07 Cr | 0.11 Cr | 0.32 Cr | 3 Cr | 5 Cr | 11 Cr | 17 Cr | Sign in free for the trailing twelve months |
| Depreciation | 1 Cr | 2 Cr | 3 Cr | 4 Cr | 12 Cr | 20 Cr | 43 Cr | 82 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 8 Cr | 4 Cr | -0.37 Cr | 12 Cr | -5 Cr | -16 Cr | -58 Cr | -80 Cr | Sign in free for the trailing twelve months |
| Tax % | 29.4% | 29.0% | 42.8% | 28.4% | -23.1% | 11.2% | 1.6% | 7.2% | Sign in free for the trailing twelve months |
| Net profit | 6 Cr | 3 Cr | -0.21 Cr | 9 Cr | -6 Cr | -14 Cr | -57 Cr | -74 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹2.26 | ₹1.12 | ₹-0.09 | ₹3.58 | ₹-2.29 | ₹-5.59 | ₹-20.68 | ₹-22.46 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | 28.2% | — | — | — | — | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 18 Cr | 25 Cr | 25 Cr | 25 Cr | 25 Cr | 26 Cr | 29 Cr | 35 Cr |
| Reserves | 51 Cr | 44 Cr | 42 Cr | 64 Cr | 55 Cr | 64 Cr | 195 Cr | 659 Cr |
| Borrowings | 0 Cr | 0 Cr | — | — | 9 Cr | 15 Cr | 6 Cr | 29 Cr |
| Other liabilities | 21 Cr | 20 Cr | 19 Cr | 49 Cr | 69 Cr | 124 Cr | 206 Cr | 406 Cr |
| Total liabilities | 90 Cr | 88 Cr | 85 Cr | 139 Cr | 158 Cr | 228 Cr | 439 Cr | 1,131 Cr |
| Fixed assets (net) | 8 Cr | 8 Cr | 8 Cr | 9 Cr | 15 Cr | 24 Cr | 56 Cr | 140 Cr |
| CWIP | 0.26 Cr | 0 Cr | 0.04 Cr | — | 3 Cr | 5 Cr | 6 Cr | 2 Cr |
| Investments | 16 Cr | 14 Cr | 10 Cr | 33 Cr | 8 Cr | 5 Cr | 54 Cr | 264 Cr |
| Loans & advances | — | — | — | — | 7 Cr | 17 Cr | 17 Cr | 37 Cr |
| Inventories | 33 Cr | 25 Cr | 28 Cr | 29 Cr | 42 Cr | 54 Cr | 106 Cr | 193 Cr |
| Trade receivables | 22 Cr | 29 Cr | 29 Cr | 36 Cr | 28 Cr | 27 Cr | 41 Cr | 74 Cr |
| Cash & bank | 0.02 Cr | 0.01 Cr | 0.02 Cr | 0.04 Cr | 0.09 Cr | 0.68 Cr | 2 Cr | 8 Cr |
| Other assets | 11 Cr | 12 Cr | 11 Cr | 32 Cr | 56 Cr | 97 Cr | 158 Cr | 414 Cr |
| Total assets | 90 Cr | 88 Cr | 85 Cr | 139 Cr | 158 Cr | 228 Cr | 439 Cr | 1,131 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | -3 Cr | 6 Cr | -0.89 Cr | 13 Cr | -2 Cr | -6 Cr | -50 Cr | -84 Cr |
| Cash from investing | 9 Cr | -4 Cr | 4 Cr | -27 Cr | 15 Cr | -13 Cr | -92 Cr | -314 Cr |
| Cash from financing | -6 Cr | -3 Cr | -2 Cr | 14 Cr | -14 Cr | 19 Cr | 145 Cr | 490 Cr |
| Net cash flow | -0.77 Cr | -0.86 Cr | 0.51 Cr | 0.95 Cr | -1 Cr | -0.11 Cr | 3 Cr | 92 Cr |
| Free cash flow (OCF − Capex) | -6 Cr | -0.63 Cr | -3 Cr | 10 Cr | -15 Cr | -6 Cr | -50 Cr | -84 Cr |
Ratios
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 11.5% | 5.7% | -0.4% | 14.2% | -2.4% | -10.9% | -20.1% | -8.6% |
| ROE % | 8.0% | 4.0% | -0.3% | 9.9% | -7.2% | -15.9% | -24.8% | -10.6% |
| Debtor days | 94 | 112 | 98 | 101 | 72 | 55 | 50 | 50 |
| Inventory days | 1028 | 709 | 508 | 528 | 873 | 1536 | 2371 | 4015 |
| Days payable | 511 | 420 | 281 | 341 | 553 | 960 | 951 | 2180 |
| Cash conversion cycle | 611 | 402 | 325 | 288 | 393 | 631 | 1470 | 1885 |
| OCF / EBITDA % | -41.9% | 122.8% | n.m. | 90.1% | -27.3% | -79.2% | — | -455.4% |
| OCF / EBITDA % (3 years) | — | — | 10.9% | 90.2% | 45.9% | 18.0% | n.m. | n.m. |
| Debt / equity | 0.00 | 0.00 | — | — | 0.11 | 0.16 | 0.03 | 0.04 |
| Current ratio | 3.15 | 3.17 | 3.36 | 2.14 | 2.08 | 1.51 | 1.83 | 1.93 |
| Net debt / EBITDA | -0.0028 | — | — | — | 1.20 | 1.85 | — | 1.13 |